Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

ASLAN Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

ASLAN PharmaceuticalsDer Umsatz und der Gewinn des Unternehmens werden voraussichtlich um 187.9% bzw. 17.9% pro Jahr zurückgehen, während der Gewinn pro Aktie voraussichtlich zurückgehen wird.

Wichtige Informationen

-17.9%

Wachstumsrate der Gewinne

-5.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.7%
Wachstumsrate der Einnahmen	-187.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Sep 14

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Jan 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ASLN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	-55	N/A	N/A	1
12/31/2024	N/A	-73	N/A	N/A	2
3/31/2024	12	-35	N/A	N/A	N/A
12/31/2023	12	-44	-47	-47	N/A
9/30/2023	12	-45	N/A	N/A	N/A
6/30/2023	12	-46	-59	-59	N/A
3/31/2023	N/A	-58	N/A	N/A	N/A
12/31/2022	N/A	-51	-38	-38	N/A
9/30/2022	N/A	-46	N/A	N/A	N/A
6/30/2022	N/A	-45	-36	-36	N/A
3/31/2022	N/A	-38	N/A	N/A	N/A
12/31/2021	N/A	-31	-34	-34	N/A
9/30/2021	N/A	-28	N/A	N/A	N/A
6/30/2021	N/A	-21	-21	-21	N/A
3/31/2021	N/A	-20	N/A	N/A	N/A
12/31/2020	N/A	-16	-15	-15	N/A
9/30/2020	N/A	-40	-15	-15	N/A
6/30/2020	0	-41	-20	-20	N/A
3/31/2020	N/A	-47	-24	-24	N/A
12/31/2019	3	-47	-26	-26	N/A
9/30/2019	3	-27	-29	-29	N/A
6/30/2019	3	-34	-34	-33	N/A
3/31/2019	3	-37	-47	-36	N/A
12/31/2018	N/A	-42	-63	-39	N/A
9/30/2018	N/A	-45	-63	-40	N/A
6/30/2018	N/A	-41	-61	-38	N/A
3/31/2018	N/A	-42	-52	-40	N/A
12/31/2017	N/A	-41	N/A	-35	N/A
9/30/2017	1	-33	N/A	-30	N/A
6/30/2017	12	-19	N/A	-14	N/A
3/31/2017	12	-14	N/A	-8	N/A
12/31/2016	11	-9	N/A	-6	N/A
9/30/2016	11	-7	N/A	-7	N/A
6/30/2016	0	-15	N/A	-13	N/A
3/31/2016	N/A	-15	N/A	-13	N/A
12/31/2015	N/A	-14	N/A	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ASLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ASLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ASLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ASLN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ASLN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ASLN in 3 Jahren voraussichtlich hoch sein wird

ASLAN Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.6% to US$16.00

Price target increased to US$5.50

Price target increased to US$5.50

Price target decreased to US$5.50

Recent updates

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

New major risk - Financial position

Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD

High number of new and inexperienced directors

New major risk - Market cap size

New minor risk - Share price stability

ASLAN Pharmaceuticals Limited Presents New Data on Eblasakimab in Atopic Dermatitis and Copd Translational Models At the 7Th Dermatology Drug Development Summit

New major risk - Negative shareholders equity

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

ASLAN Pharmaceuticals Presents New Data from Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker

New major risk - Financial position

Aslan Pharmaceuticals Limited Announces Phase 2B Treatment of Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2B Study in Atopic Dermatitis

Aslan Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Price target decreased by 8.6% to US$16.00

Aslan Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

Price target increased to US$5.50

Aslan Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking E-Posters At the 51St Annual European Society for Dermatological Research Meeting

Price target increased to US$5.50

ASLAN Pharmaceuticals Limited Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Price target decreased to US$5.50

ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Aslan Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation At the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals Limited Screens the First Patient in Its Phase 2B Dose-Ranging Clinical Study of Eblasakimab in Adults with Moderate-To-Severe Atopic Dermatitis

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals Limited announced that it expects to receive SGD 45 million in funding from K2 HealthVentures

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of $60 million.

ASLAN Pharmaceuticals Limited announced that it expects to receive $17.999999 million in funding from Vivo Capital, LLC, Citadel Enterprise Americas LLC

ASLAN Pharmaceuticals Announces Executive Changes

ASLAN Pharmaceuticals Limited Announces New Data from a Study Conducted by University of Liverpool, UK

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Aslan Pharmaceuticals Limited Announces Clinical Development of Aslan004

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

ASLAN Pharmaceuticals Limited Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

ASLAN Pharmaceuticals Limited(GTSM:6497) dropped from S&P Global BMI Index

ASLAN Pharmaceuticals Announces Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken